← Back to Trade Analysis
Current Tariff: 50%

US-India Trade Analysis

Country
India
US Import Rank
#10
Import Value
$91 billion
Trade Agreement
None (Bilateral Trade Agreement under negotiation)

Last Updated:

Quick Facts

MetricValue
US Import Rank#10
2024 Import Value~$91 billion
% of US Imports2.7%
2024 Tariff Rate2-3% average
Current Tariff Rate50% (highest among major partners)
Trade AgreementNone (Bilateral Trade Agreement under negotiation)
US Trade Balance-$45.7 billion deficit

Trade Framework

No Formal Agreement

Status: The US and India do not have a free trade agreement.

Historical Context

DateEvent
June 5, 2019India lost GSP (Generalized System of Preferences) benefits
2019-2024Trade under WTO MFN rules
Feb 13, 2025Bilateral Trade Agreement negotiations announced

GSP Revocation

In 2019, Trump’s first administration revoked India’s GSP benefits:

  • Affected $5.6 billion in exports
  • India was largest GSP beneficiary
  • Revoked due to market access concerns

2024 Baseline Tariff Structure

Product Category2024 US RateNotes
Most goods2-3%MFN rates
Pharmaceuticals~0.01%Near duty-free
Textiles/footwear3-9%Higher rates
Gems/jewelryLowMFN rates

India’s Tariffs on US Goods (for context)

CategoryIndia’s Rate
Overall average16.2%
Agricultural36.7%
Non-agricultural13.0%

India’s tariffs are among the highest of any major economy.

2025 Tariff Changes

Timeline

Apr 2, 2025     "Liberation Day" - 10% baseline + 26% reciprocal
Jul 30, 2025    25% implemented
Aug 27, 2025    Additional 25% (Russia oil penalty)
Total:          50% tariff on most goods

The 50% Tariff

India faces a cumulative 50% tariff—the highest among major US trading partners, tied with Brazil.

ComponentRateReason
Baseline reciprocal10%Applied to all countries
India-specific reciprocal25%High Indian tariffs cited
Russia oil penalty25%IEEPA - continued Russian oil imports
Total50%Combined rate

Current Tariff Structure (January 2026)

Product CategoryCurrent RateNotes
Most goods50%Highest rate tier
Generic pharmaceuticals0%Exempt
Semiconductors0%Exempt
Critical minerals0%Exempt
Energy products0%Exempt

Exemptions

Generic Pharmaceuticals (Critical)

StatisticDetail
India’s share of US generics47%
Share of essential US drugs70%
Key medicationsMetformin, Atorvastatin, Losartan

Why Exempt: Tariffs would cause shortages and price increases for critical medications.

Branded vs. Generic Drugs

TypeTariffStatus
Generic drugs0%Exempt
Branded/patented drugs100%Effective Oct 1, 2025
Exception0%Companies building US plants

Other Exemptions

ProductStatus
SemiconductorsExempt
Critical mineralsExempt
Energy productsExempt

Economic Effects

GDP Impact Projections

SourceProjected Impact
Goldman Sachs-0.6 percentage points
MUFG Research-1.0% GDP (sustained 50%)
Deloitte-0.3 to -0.4% of GDP
Consensus-0.2 to -0.5% growth decline

Export Impact

MetricDetail
India’s exports to US$87 billion annually
Share of Indian exports18%
Share of GDP2.5%
Projected loss$5-8 billion
GTRI projectionExports could fall from $86.5B to $50B by 2026

Employment Impact

ScenarioJobs at Risk
Direct manufacturing10 million workers
Including induced effectsUp to 21 million workers

Regional Hubs Affected

LocationIndustry
SuratDiamonds/gems
TirupurTextiles
MumbaiVarious manufacturing

Currency Impact

MetricChange
Rupee depreciation4-5% against USD
January 202586.23 INR/USD
December 2025~90 INR/USD

Key Products Affected

Gems and Jewelry ($10-12 billion)

MetricDetail
Share of global gems exports30-33%
Current tariff50%
Projected turnover declineUp to 50%

Textiles and Apparel

MetricDetail
Major export categoryYes
Current tariff50%
Projected export collapse70%
Competing countriesBangladesh, Vietnam

Shrimp and Marine Products

MetricDetail
Share directed to USOver 30%
VulnerabilityHigh
Current tariff50%

IT Services

MetricDetail
Exposure to US~9% of Nifty 50
StatusNOT targeted (goods tariffs only)
ImpactRelatively insulated

Pharmaceuticals

TypeShareTariff
Generic drugs85-90% of pharma exports0%
Branded drugs10-15%100%

Major Generic Exporters (largely unaffected):

  • Cipla
  • Sun Pharma
  • Dr. Reddy’s
  • Lupin

Negotiations

Current Status (January 2026)

StatusDetail
Progress”Very near” to initial framework
TimelinePotential announcement by March 2026
Outcome if successfulTariffs reduced to 15-20%

Key Meetings

DateParticipantsTopic
Feb 13, 2025Modi-TrumpBTA negotiations announced
April 2025VP VanceTerms of Reference finalized
Dec 10-11, 2025Gor, Switzer, Goyal, AgrawalFramework discussions

Key Sticking Points

IssueUS PositionIndia Position
Agricultural accessDemands reductionsProtecting farmers
Dairy marketWants accessProtecting domestic
Russian oilSanctions complianceEnergy security
Non-tariff barriersRemoveDefending practices

India’s Stance

PositionDetail
RetaliationNone announced, but reserved WTO rights
DeadlinesWill not negotiate under pressure
MarketsDiversifying to EU, Gulf
StatementWill not “bow down” to US

Significant Events

DateEventImpact
Jun 5, 2019GSP revoked$5.6B affected
Apr 2, 202536% tariff announcedMajor escalation
Jul 30, 202525% implemented
Aug 27, 2025+25% Russia penaltyTotal reaches 50%
Dec 2025Framework talksNearing deal

India’s Response Strategy

No Retaliation (Yet)

Unlike China, India has not imposed retaliatory tariffs:

  • Reserved right to act through WTO
  • Maintaining negotiating posture
  • Avoiding escalation

Market Diversification

New FocusStrategy
European UnionCloser trade ties
Gulf countriesExpanded engagement
ASEANRegional integration

Domestic Measures

ActionPurpose
Production incentivesReduce export dependence
Import substitutionBuild domestic capacity
Export promotionNew markets

Current Status (January 2026)

What’s in Effect

  • 50% tariff on most goods (highest tier)
  • 0% on generic pharmaceuticals
  • 0% on semiconductors and critical minerals
  • 100% on branded drugs

Negotiations

  • Framework deal “very near”
  • Could reduce to 15-20%
  • No formal deadline

Outstanding Issues

  • Russian oil imports remain contentious
  • Agricultural market access
  • Non-tariff barriers
  • High Indian tariffs on US goods

Outlook

India faces the most challenging tariff situation among major US trading partners. The 50% rate severely impacts manufacturing exports, particularly gems, textiles, and marine products. However, the pharmaceutical exemption protects India’s most critical export sector. Ongoing negotiations offer hope for reduction to 15-20%, but fundamental issues around agricultural access and Russian oil remain unresolved.

Sources